Milestone Pharmaceuticals (MIST) risk factors
Item 1A of every Milestone Pharmaceuticals Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors83 risks11 new10 dropped22 reworded
Milestone added risks highlighting wholesaler returns for CARDAMYST, massive warrant dilution, and potential TrumpRx pricing mandates. The company updated existing sections to emphasize commercializing CARDAMYST for PSVT.
Filed Mar 20, 2026 - FY2024 10-K risk factors82 risks
Milestone Pharmaceuticals faces ongoing operating losses and an accumulated deficit of $367.5 million as a clinical-stage biotech. The company is heavily dependent on the clinical development, regulatory approval, and commercialization of its lead product candidate, etripamil, for PSVT and AFib-RVR. Substantial additional capital will be required to fund operations, as existing cash is projected to last for at least the next 12 months.
Filed Mar 13, 2025